가바펜틴 시장 예측(-2034년) : 제품 유형, 종류, 투여 경로, 구입 형태, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Gabapentin Market is accounted for $2.6 billion in 2026 and is expected to reach $4.6 billion by 2034 growing at a CAGR of 7.4% during the forecast period. Gabapentin is a pharmaceutical compound used primarily as an anticonvulsant and to alleviate neuropathic pain which mimic the neurotransmitter gamma-aminobutyric acid (GABA). It is approved by the U.S. Food and Drug Administration (FDA), and is employed in the treatment of various medical conditions, including epilepsy, postherpetic neuralgia, and restless legs syndrome. The drug's versatility in addressing neurological disorders and chronic pain has made it a valuable asset in modern medicine.

According to a report, gabapentin ranks sixth in prescribed medication in the United States in 2020. Nearly, 57 million prescriptions were written for the drug in the country in 2020.

Market Dynamics:

Driver:

Increase in awareness

Healthcare professionals and patients are becoming more informed about the drug's efficacy in managing various neurological disorders and neuropathic pain conditions. Physicians are increasingly prescribing Gabapentin based on a deeper understanding of its mechanisms of action and the diverse range of conditions it can effectively address. In addition, the evolving landscape of patient-centered healthcare encourages informed decision-making, making awareness a crucial factor in driving this market.

Restraint:

Misuse and abuse

Gabapentin misuse can involve taking higher doses than prescribed, using it without a prescription, or combining it with other substances to intensify the desired effects. Abuse of gabapentin can result in various adverse effects, including dizziness, sedation, impaired coordination, blurred vision, and cognitive difficulties. Furthermore, abrupt discontinuation of gabapentin after prolonged misuse or abuse can result in withdrawal symptoms such as anxiety, insomnia, and restlessness, significantly hampering this market expansion.

Opportunity:

Telehealth expansion

The expansion of telehealth services serves healthcare and positively impacts the accessibility of this medication by transforming easy delivery for individuals requiring gabapentin for neurological disorders and neuropathic pain. Telehealth allows healthcare providers to conduct remote consultations, prescribe medications, and monitor patients' conditions from a distance. Further, telehealth enables healthcare professionals to monitor patients remotely, address concerns promptly, and optimize medication management, which is propelling this market

Threat:

Side effects and tolerance

The prevalence of side effects poses challenges for healthcare providers in balancing the therapeutic benefits of Gabapentin with its potential drawbacks. Patient-specific factors, such as age, underlying health conditions, and concurrent medications, can influence the likelihood and severity of side effects. Moreover, the presence of side effects may necessitate additional medical interventions, contributing to healthcare costs and resource utilization and thereby hindering market growth.

Covid-19 Impact

The COVID-19 pandemic has had several negative impacts on the Gabapentin market. Supply chain disruptions, lockdown measures, and shifts in healthcare priorities have collectively contributed to challenges in the production, distribution, and consumption of gabapentin. Economic uncertainties and financial strains on healthcare systems have prompted cost-cutting measures, potentially influencing the affordability of Gabapentin. Moreover, reduced patient visits to healthcare providers may have led to a decline in new prescriptions and refills, affecting overall market demand.

The capsule segment is expected to be the largest during the forecast period

The capsule segment is estimated to hold the largest share. These are pharmaceutical products widely prescribed for neurological disorders and neuropathic pain that are efficient in managing conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Factors such as research and development initiatives, regulatory approvals, and strategic collaborations influence market dynamics. Furthermore, a focus on innovation, safety, and accessibility continues to be a vital contributor to the broader pharmaceutical market, driving this segment's growth.

The parenteral segment is expected to have the highest CAGR during the forecast period

The parenteral segment is anticipated to have highest CAGR during the forecast period due to distinct advantages, particularly in situations where oral intake may be challenging, such as for patients experiencing nausea, vomiting, or those with difficulty swallowing. This mode of delivery enhances treatment compliance and ensures patients receive the prescribed dosage accurately. Additionally, for individuals requiring rapid onset of action or precise dosage control, parenteral formulations of gabapentin provide an effective alternative, boosting this segment's expansion.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to its significant presence in the pharmaceutical landscape, addressing neurological disorders and neuropathic pain. Key markets such as Pfizer Inc., Teva Pharmaceuticals Ltd., Glenmark Pharmaceuticals Limited, and Cipla USA Inc. have become cornerstones in the management of conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Furthermore, regulatory oversight from agencies like the U.S. Food and Drug Administration (FDA) and Health Canada ensures compliance with safety standards and effective distribution in this region.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period, owing to its efficacy in managing conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Pharmaceutical companies engage in manufacturing and marketing activities to meet the increasing demand for Gabapentin, aiming to provide effective solutions for individuals grappling with neurological conditions in Europe. In addition, factors such as the rising prevalence of neurological disorders, an aging population, and an increased awareness of chronic pain management are boosting this region's expansion.

Key players in the market

Some of the key players in the Gabapentin Market include Amneal Pharmaceuticals LLC., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd, Marksans Pharma, Novartis AG, Alkem Labs, Jiangsu Nhwa Pharmaceutical Co., Ltd, Aurobindo Pharma, Apotex Inc, Viatris Inc, Arbor Pharmaceuticals, LLC, Pfizer Inc, Teva Pharmaceuticals Ltd, Glenmark Pharmaceuticals Limited, Ascend Laboratories, LLC and Cipla USA, Inc.

Key Developments:

In December 2023, Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.

In October 2023, Zydus Lifesciences Company and Sun Pharmaceutical Industries Limited announced that both companies have entered into a licensing agreement to co-market an innovative drug, Desidustat in India.

In January 2023, Sun Pharmaceutical Industries Limited and Concert Pharmaceuticals, Inc. announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment in equity value.

Products Covered:

• Tablet
• Capsule
• Other Products

Types Covered:

• Generic
• Branded
• Other Types

Route of Administrations Covered:

• Parenteral
• Oral
• Intravenous
• Other Route of Administrations

Mode of Purchase Covered:

• Prescription
• Over the Counter(OTC)
• Retail

Applications Covered:

• Neuropathic Pain
• Epilepsy
• Restless Legs Syndrome
• Other Applications

End Users Covered:

• Online Pharmacies
• Hospital Pharmacy
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Gabapentin Market, By Product

• 5.1 Introduction
• 5.2 Tablet
• 5.3 Capsule
• 5.4 Other Products

6 Global Gabapentin Market, By Type

• 6.1 Introduction
• 6.2 Generic
• 6.3 Branded
• 6.4 Other Types

7 Global Gabapentin Market, By Route of Administration

• 7.1 Introduction
• 7.2 Parenteral
• 7.3 Oral
• 7.4 Intravenous
• 7.5 Other Route of Administrations

8 Global Gabapentin Market, By Mode of Purchase

• 8.1 Introduction
• 8.2 Prescription
• 8.3 Over the Counter (OTC)
• 8.4 Retail

9 Global Gabapentin Market, By Application

• 9.1 Introduction
• 9.2 Neuropathic Pain
• 9.3 Epilepsy
• 9.4 Restless Legs Syndrome
• 9.5 Other Applications

10 Global Gabapentin Market, By End User

• 10.1 Introduction
• 10.2 Online Pharmacies
• 10.3 Hospital Pharmacy
• 10.4 Other End Users

11 Global Gabapentin Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Amneal Pharmaceuticals LLC.
• 13.2 Intas Pharmaceuticals Ltd.
• 13.3 Sun Pharmaceutical Industries Ltd
• 13.4 Marksans Pharma
• 13.5 Novartis AG
• 13.6 Alkem Labs
• 13.7 Jiangsu Nhwa Pharmaceutical Co., Ltd
• 13.8 Aurobindo Pharma
• 13.9 Apotex Inc
• 13.10 Viatris Inc
• 13.11 Arbor Pharmaceuticals, LLC
• 13.12 Pfizer Inc
• 13.13 Teva Pharmaceuticals Ltd
• 13.14 Glenmark Pharmaceuticals Limited
• 13.15 Ascend Laboratories, LLC
• 13.16 Cipla USA, Inc.